ClinicalTrials.gg
Active, not recruitingNCT05876923Updated Nov 16, 2026

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

An interventional study of Biospecimen Collection and Cardiopulmonary Exercise Testing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Indolent Non-hodgkin Lymphoma, sponsored by Mayo Clinic. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic — 8 open to participants now, 12 under way, 1 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Mayo Clinic.

Enrollment
13th of 36
65 · median 40
Started
2023
with 2 others
No phase
3 of 45
none open now
Primary completion
2025-09
later than 0 of 11 live
Registered
40th of 45
by date

Among the 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic, this one is the 13th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2023, is one of 3 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 40th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic, or all of them as a file.
02

Study summary

This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.

Read the detailed description

PRIMARY OBJECTIVES:

I. Determine how circulating immune cell abundance and function (via cell counts \& cytokine profile) of CLL patients respond to acute (single bout) maximal exercise and how this differs from the response observed in group of age-matched controls by monitoring cardiopulmonary parameters and mobilization of immune cell phenotypes.

II. Determine how circulating immune cell mobilization and function (cell counts \& cytokine profile) of CLL patients respond to a 12-week semi-supervised training program of moderate to high intensity, aerobic based exercise.

III. Evaluate the effectiveness of 12-weeks of semi-supervised exercise training (ET) versus (vs.) usual care (UC) at reducing cancer-related side effects and improving quality of life (QOL) and physical fitness in individuals with indolent non-Hodgkin (NHL) lymphoma during or after treatment.

IV. Determine that extent to which 12-weeks of semi-supervised ET can modify circulating immune cell mobilization and immune function in individuals with indolent NHL during or after treatment compared to UC.

V. Development of a forward-chaining AI expert system using both manual and physiology derived feedback to optimize training results and compare its efficacy at reducing cancer-related side effects and improving quality of life (QOL) and physical fitness in individuals with indolent NHL and CLL to that of the semi-supervised ET.

OUTLINE: CLL patients and healthy participants are assigned to Aim 1. CLL patients who complete all Aim 1 activities are assigned to Aim 2. Patients with indolent NHL will be assigned to Aims 3 and 4.

AIM 1: Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (cardiopulmonary exercise testing [CPET]), and undergo collection of blood samples on study. Participants may also undergo dual X-ray absorptiometry (DEXA) scan on study.

AIM 2: CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.

AIMS 3-4: Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6-minute walk test (6MWT). Patients are then randomized to 1 of 2 arms.

ARM I: Patients receive usual care on study.

ARM II: Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.

AIM 5: All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.

After completion of study intervention, patients are followed up every 6 months (Aims 2-4) or annually (Aim 5) for 3 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Indolent Non-hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English speaking
  • Between the ages of 18-80
  • confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL/SLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study

Exclusion criteria

Exclusion Criteria:

  • Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, [COPD], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker
  • Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Aim 1 (vitals, spirometry, CPET, blood samples, DEXA)

    Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study.

    Procedure: Biospecimen Collection · Other: Cardiopulmonary Exercise Testing · Procedure: Dual X-ray Absorptiometry · Other: Electronic Health Record Review · Procedure: Physical Examination · Other: Questionnaire Administration · Procedure: Spirometry

  • Experimental
    Aim 2 (aerobic based training program, Aim 1 activities)

    CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.

    Procedure: Biospecimen Collection · Other: Cardiopulmonary Exercise Testing · Procedure: Dual X-ray Absorptiometry · Other: Electronic Health Record Review · Other: Exercise Intervention · Procedure: Physical Examination · Other: Questionnaire Administration · Procedure: Spirometry

  • Active comparator
    Aims 3-4 arm I (indolent NHL usual care)

    Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients receive usual care on study.

    Procedure: Biospecimen Collection · Other: Cardiopulmonary Exercise Testing · Procedure: Dual X-ray Absorptiometry · Other: Electronic Health Record Review · Procedure: Physical Examination · Other: Questionnaire Administration · Procedure: Spirometry · Other: Physical Performance Testing · Other: Best Practice

  • Active comparator
    Aims 3-4 arm II (indolent NHL aerobic based training program)

    Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.

    Procedure: Biospecimen Collection · Other: Cardiopulmonary Exercise Testing · Procedure: Dual X-ray Absorptiometry · Other: Electronic Health Record Review · Other: Exercise Intervention · Procedure: Physical Examination · Other: Questionnaire Administration · Procedure: Spirometry · Other: Physical Performance Testing · Other: Best Practice

  • Experimental
    Aim 5 (repeat baseline activities)

    All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.

    Procedure: Biospecimen Collection · Other: Cardiopulmonary Exercise Testing · Procedure: Dual X-ray Absorptiometry · Other: Electronic Health Record Review · Procedure: Physical Examination · Other: Questionnaire Administration · Procedure: Spirometry · Other: Physical Performance Testing

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OtherCardiopulmonary Exercise Testing

    Undergo CPET

    Also known as: CPET, CPX

  • ProcedureDual X-ray Absorptiometry

    Undergo DEXA scan

    Also known as: BMD scan, bone mineral density scan, DEXA, DEXA (Bone Density), DEXA Scan, dual energy x-ray absorptiometric scan, Dual Energy X-ray Absorptiometry, Dual X-Ray Absorptometry, DXA, DXA SCAN

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherExercise Intervention

    Undergo aerobic based training program

  • ProcedurePhysical Examination

    Undergo measurement of height/weight and vital signs

    Also known as: Assessment, General Examination, Physical, Physical Assessment, Physical Exam, Physical examination procedure (procedure), physical_exam

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureSpirometry

    Undergo spirometry

  • OtherPhysical Performance Testing

    Undergo muscular strength and functional endurance measurements

    Also known as: Physical Fitness Testing, Physical Function Testing

  • OtherBest Practice

    Receive usual care

    Also known as: standard of care, standard therapy

06

What researchers measure

Primary outcomes

  1. Assess circulating immune cell abundance and function pre-intervention

    A standardized questionnaire will be administered to assess levels of past and current physical activity. Baseline measurement of pulmonary function (PFT) will be collected and possibly a body composition scan via dual x-ray absorptiometry (DEXA). While subjects perform cardiopulmonary exercise testing (CPET), cardiopulmonary vitals will be assessed and monitored throughout exercise and in recovery. A 40 mL venous blood sample will be drawn at baseline and post exercise (80 mL total), along with finger prick measures of blood lactate at rest and early recovery. Blood samples will be evaluated to determine how circulating immune cell abundance and function (via cell counts \& cytokine profile) of chronic lymphocytic leukemia (CLL) patients respond to acute (single bout) maximal exercise and how this differs from the response observed in group of age-matched controls by monitoring cardiopulmonary parameters and mobilization of immune cell phenotypes.

    Time frame: Baseline

  2. Assess circulating immune cell mobilization and function post-intervention

    Each subject will participate in a 12-weeks exercise program (3 times per week) at a moderate to high exercise intensity level based upon the results of their cardiopulmonary exercise testing (CPET). Upon completion of the program, subjects will return to the laboratory for post testing using the same techniques as used during the baseline. Venous blood samples drawn at rest after the program will be used to determine how circulating immune cell mobilization and function (cell counts and cytokine profile) of CLL patients respond to intervention. Usual descriptive statistics will be performed - means, standard deviations, and ranges. Comparisons within a group over time or pre/post will be performed using paired t-tests, while comparisons between groups will be performed using unpaired t-tests or where necessary using ANOVA. Comparisons will be made based on absolute values as well as changes during a test.

    Time frame: 12 weeks (at end of 12-week intervention)

Secondary outcomes

  1. Assess circulating immune cell mobilization and function in follow-up

    Each subject will participate in a 12-weeks exercise program (3 times per week) at a moderate to high exercise intensity level based upon the results of their cardiopulmonary exercise testing (CPET). Upon completion of the program, subjects will return to the laboratory for post testing using the same techniques as used during the baseline. Venous blood samples drawn at rest after the program will be used to determine how circulating immune cell mobilization and function (cell counts and cytokine profile) of CLL patients respond to intervention. Usual descriptive statistics will be performed - means, standard deviations, and ranges. Comparisons within a group over time or pre/post will be performed using paired t-tests, while comparisons between groups will be performed using unpaired t-tests or where necessary using ANOVA. Comparisons will be made based on absolute values as well as changes during a test.

    Time frame: Annually up to 3 years

  2. Fatigue - SCFS (indolent NHL only)

    The Schwartz Cancer Fatigue Scale (SCFS) is a 6-item instrument measuring physical and perceptual dimensions of fatigue experienced over the past 2 to 3 days. Each item is scored on a 5-point scale from 1 (not at all) to 5 (extremely) with scores ranging from 6 to 36. Higher scores indicate greater perception of fatigue.

    Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years

  3. Fatigue - FACIT-F (indolent NHL only)

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 13-item questionnaire used to measure fatigue levels and impact of fatigue on daily activities over the past 7 days. Each item is scored on a 5-point scale from 0 (not at all) to 4 (very much). total scores range from 0 to 52 with higher scores indicating lower level of fatigue.

    Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years

  4. Quality of Life - EORTC-QLQ-C30 (indolent NHL only)

    The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 is a 30-item questionnaire a questionnaire used to assess the quality of life of cancer patients. Twenty-eight questions are answered on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, and 4= very much), and two questions are answered on a scale of 1-7 (1= very poor and 7=excellent). Higher summary scores indicate better health related quality of life.

    Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years

  5. Physical Activity - GPAQ (indolent NHL only)

    The Global Physical Activity Questionnaire (GPAQ) is a 16-item survey used to measure physical activity levels and sedentary behavior over the past week. Participants record different types and duration of physical activity in a typical week. Overall responses is scored by calculating Metabolic Equivalent of Task (MET) minutes and classifying physical activity levels as low, moderate, or high based on World Health Organization (WHO) guidelines.

    Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years

07

Study locations

2 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Sep 2025, 27 months.

Of 38 non-industry interventional studies with no phase under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 134. This study's 27 months is below that.

Counting every sponsor, half of 40 studies reached it within 42 months; a quarter within 27 and three quarters within 134.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Mar 2028 → Sep 2025 and completion Apr 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 26, 2023
StartActual
Jun 12, 2023
Primary completionActual
Sep 18, 2025was Mar 2028
CompletionEst.
Sep 18, 2029was Apr 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Primary completion
Mar 13, 2028→Sep 18, 2025 (actual)
Nov 16, 2026
Study completion
Apr 2028→Sep 18, 2029
Nov 16, 2026
Enrollment
70 (estimated)→65 (actual)
Nov 16, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAssess circulating immune cell mobilization and function post-interventionUp to 12 weeks → 12 weeks (at end of 12-week intervention)
  • DescriptionAssess circulating immune cell mobilization and function post-intervention: how it is measured was reworded
Nov 16, 2026
Secondary outcomes
5 added
What changed in the outcomes
  • AddedAssess circulating immune cell mobilization and function in follow-upTime frame: Annually up to 3 years
  • AddedFatigue - SCFS (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
  • AddedFatigue - FACIT-F (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
  • AddedQuality of Life - EORTC-QLQ-C30 (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
  • AddedPhysical Activity - GPAQ (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 13, 2028→Sep 18, 2025 (now actual)
    Study completion Apr 2028→Sep 18, 2029
    Enrollment 70 (estimated)→65 (actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAssess circulating immune cell mobilization and function post-interventionUp to 12 weeks → 12 weeks (at end of 12-week intervention)
    • DescriptionAssess circulating immune cell mobilization and function post-intervention: how it is measured was reworded
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedAssess circulating immune cell mobilization and function in follow-upTime frame: Annually up to 3 years
    • AddedFatigue - SCFS (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
    • AddedFatigue - FACIT-F (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
    • AddedQuality of Life - EORTC-QLQ-C30 (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
    • AddedPhysical Activity - GPAQ (indolent NHL only)Time frame: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05876923
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jun 12, 2023
Primary completion
Sep 18, 2025
Completion
Sep 18, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Michael P. Gustafson, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion